TFS Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

TFS Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-14,750	Closed	-$454K	–	659
2017 Q1	$454K	Buy	+14,750	New	+$459K	0.15%	256
2016 Q2	–	Sell	-17,487	Closed	-$514K	–	1014
2016 Q1	$514K	Buy	+17,487	New	+$487K	0.07%	431
2015 Q3	–	Sell	-121,085	Closed	-$5.45M	–	936
2015 Q2	$5.45M	Buy	121,085 +99,470	+460%	+$3.87M	0.53%	19
2015 Q1	$662K	Sell	21,615 -3	-0%	-$117	0.06%	461
2014 Q4	$1.1M	Sell	21,618 -72,153	-77%	-$3.23M	0.1%	303
2014 Q3	$3.71M	Buy	+93,771	New	+$3.74M	0.32%	62
2013 Q4	–	Sell	-20,168	Closed	-$462K	–	1514
2013 Q3	$462K	Sell	20,168 -1,981	-9%	-$37.9K	0.02%	917
2013 Q2	$392K	Buy	+22,149	New	+$432K	0.02%	1014

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

TFS Capital's ENTA Position: Q2 2017 in Review

TFS Capital sold out of Enanta Pharmaceuticals (ENTA) in Q2 2017, closing a stake of 14,750 shares — an estimated $454K sold.

TFS Capital first reported a position in ENTA in Q2 2013 and held it in 8 quarters. The position peaked at $5.45M in Q2 2015. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2017.

TFS Capital reported no remaining Enanta Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 14,750 Enanta Pharmaceuticals shares in Q2 2017, an estimated $454K.
TFS Capital first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 8 quarters.
TFS Capital's Enanta Pharmaceuticals position peaked at $5.45M in Q2 2015.
122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.